[(2R)-2-Cyclohexyl-2-(3H-inden-1-yl)ethyl]diphenylphosphine | 497869-48-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: [(2R)-2-Cyclohexyl-2-(3H-inden-1-yl)ethyl]diphenylphosphine
• 英文别名: [(2R)-2-cyclohexyl-2-(3H-inden-1-yl)ethyl]-diphenylphosphane
• CAS: 497869-48-4
• 化学式: C₂₉H₃₁P
• 分子量: 410.539
• InChiKey: WCPLVVFKLVLVLT-GDLZYMKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  di(rhodium)tetracarbonyl dichloride 、 [(2R)-2-Cyclohexyl-2-(3H-inden-1-yl)ethyl]diphenylphosphine 在 n-BuLi 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以36%的产率得到(η5:η1-indenyl-CH(Cy)CH2PPh2)Rh(CO)
  参考文献：
  名称：

  Induction of Planar Chirality in Formation of (η⁵:η¹-1-(1-Cyclohexyl-2-(diphenylphosphino)ethyl)indenyl)carbonylrhodium and (η⁵:η¹-1-(2-Phenyl-2- (diphenylphosphino)ethyl)indenyl)carbonylrhodium

  摘要：

  The enantiopure bidentate indenyl-phosphine ligands (1S)-[2-(3H-inden-1-yl)-1-phenylethyl] diphenylphosphine (9) and [(2R)-2-cyclohexyl-2-(3H-inden-1-yl)ethyl]diphenylphosphine (18) were synthesized in 20% yield and three steps from (R)-styrene oxide and in 61% yield and four steps from vinylcyclohexane, respectively. In both cases ring opening of a spirocyclopropane-1,1'-indene with potassium diphenylphosphide was a key step. Addition of the lithium salts of 9 and 18 to [Rh(mu -Cl)(CO)(2)](2) gave (eta (5):eta (1)-indenyl-CH2CH(Ph)PPh2)RhCO and (eta (5):eta (1)-indenyl-CH(Cy)CH2PPh2)RhCO as 75:25 and 78:22 mixtures of diastereoisomers, from which the major complexes were readily obtained by crystallization. The chiral centers in the linking chain beta and alpha to the indenyl ring had thus induced good planar chirality of the complexed indenyl moiety. Both complexes were characterized by X-ray crystallography.

  DOI：

  10.1021/om010367s

文献信息

• Erythropoietin production accelerator
  申请人：Imagawa Shigehiko

  公开号：US20060040986A1

  公开（公告）日：2006-02-23

  The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, R 1 , R 2 and R 3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; W 1 and W 2 each independently represent N or CH; X represents O, NR 4 , CONR 4 or NR 4 CO; R 4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

  本发明涉及一种预防或治疗由于红细胞生成素减少引起的病理状态，或用于贫血，慢性贫血，肾性贫血，再生障碍性贫血或纯红细胞再生障碍的药物，该药物包含以下式（1）所表示的环状胺化合物作为活性成分：其中，R1，R2和R3各自独立地表示氢原子，卤素原子，羟基，烷基，卤代烷基，烷氧基，烷硫基，羧基，烷氧羰基或烷酰基；W1和W2各自独立地表示N或CH；X表示O，NR4，CONR4或NR4CO；R4表示氢原子，或烷基，烯基，炔基，取代或未取代芳基，取代或未取代杂芳基，取代或未取代芳基甲基，或取代或未取代杂芳基甲基基团；l，m和n各自表示0或1的数字，或其盐或溶剂化物。
• ERYTHROPOIETIN PRODUCTION ACCELERATOR
  申请人：Kowa Co., Ltd.

  公开号：EP1568691A1

  公开（公告）日：2005-08-31

  The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein,    R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;    W1 and W2 each independently represent N or CH;    X represents O, NR4, CONR4 or NR4CO;    R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and    l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.

  本发明涉及一种预防或治疗剂，用于治疗因促红细胞生成素生成减少而引起的病理状况，或用于治疗贫血，或用于治疗慢性贫血、肾性贫血、再生障碍性贫血或单纯红细胞增生症，该剂作为一种活性成分，包括由下式(1)代表的环胺类化合物： 其中 R1、R2 和 R3 各自独立地代表氢原子、卤素原子或羟基、烷基、卤素取代的烷基、烷氧基、烷硫基、羧基、烷氧羰基或烷酰基； W1 和 W2 各自独立地代表 N 或 CH； X 代表 O、NR4、CONR4 或 NR4CO； R4 各自代表氢原子或烷基、烯基、炔基、取代或未取代的芳基、取代或未取代的杂芳基、取代或未取代的芳烷基或取代或未取代的杂烷基；以及 l、m 和 n 各代表 0 或 1，或其盐或其溶液。
• CHIRAL ORGANOMETALLIC COMPOUNDS FOR USE IN ASYMMETRIC SYNTHESIS
  申请人：Avecia Limited

  公开号：EP1417030A1

  公开（公告）日：2004-05-12
• US7019158B1
  申请人：——

  公开号：US7019158B1

  公开（公告）日：2006-03-28
• [EN] CHIRAL ORGANOMETALLIC COMPOUNDS FOR USE IN ASYMMETRIC SYNTHESIS<br/>[FR] COMPOSES ORGANOMETALLIQUES CHIRAUX S'UTILISANT DANS UNE SYNTHESE ASYMETRIQUE
  申请人：AVECIA LTD

  公开号：WO2003013724A1

  公开（公告）日：2003-02-20

  Chiral organometallic compounds are provided which comprise certain non-symmetrically substituted cyclopentadiene complexed to a transition metal. The cyclopentadiene has a second coordinating group which also complexes the transition metal and is attached to the cyclopentadiene by means of a chiral connecting chain. Preferred transition metals include rhodium, ruthenium, iridium, cobalt, iron, manganese, chromium, tungsten, molybdenum, nickel, palladium, or platinum. These chiral organometallic compounds find use in asymmetric synthesis to produce chiral compounds.